A biomarker-forward, focused, target-associated prospective approach specifically address biomarkers to select patients for therapy. Alternatively, an agnostic, trial-backwards, retrospective approach would apply biased selection with biological validation of translational endpoints against patient outcome in targeted agents’ trials.